These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26821784)

  • 1. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population.
    Fabrizi F; Martin P; Messa P
    Int J Artif Organs; 2015 Dec; 38(12):625-31. PubMed ID: 26821784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
    Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
    Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
    Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
    Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
    Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines.
    Grzegorzewska AE
    Expert Rev Vaccines; 2014 Nov; 13(11):1317-26. PubMed ID: 25148051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial.
    Fabrizi F; Cerutti R; Garcia-Agudo R; Bellincioni C; Porata G; Frontini G; Aoufi-Rabih S; Messa P
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):905-912. PubMed ID: 32144074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
    Janssen JM; Heyward WL; Martin JT; Janssen RS
    Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients.
    Beran J
    Expert Opin Biol Ther; 2008 Feb; 8(2):235-47. PubMed ID: 18194079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 33423842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients.
    Fabrizi F; Dixit V; Messa P; Martin P
    Aliment Pharmacol Ther; 2010 Sep; 32(6):756-62. PubMed ID: 20662784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
    Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
    Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus vaccine and chronic kidney disease. The advances.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(2):115-122. PubMed ID: 36165374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease.
    Fabrizi F; Ganeshan SV; Dixit V; Martin P
    Aliment Pharmacol Ther; 2006 Sep; 24(5):789-96. PubMed ID: 16918882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin use and immunogenicity of hepatitis B virus vaccine in chronic kidney disease patients: a meta-analysis.
    Fabrizi F; Dixit V; Martin P; Messa P
    Kidney Blood Press Res; 2012; 35(6):504-10. PubMed ID: 22813903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.